PMID- 29098549 OWN - NLM STAT- MEDLINE DCOM- 20171205 LR - 20211204 IS - 1573-2568 (Electronic) IS - 0163-2116 (Linking) VI - 62 IP - 12 DP - 2017 Dec TI - The GAS5/miR-222 Axis Regulates Proliferation of Gastric Cancer Cells Through the PTEN/Akt/mTOR Pathway. PG - 3426-3437 LID - 10.1007/s10620-017-4831-4 [doi] AB - BACKGROUND: Several lines of evidence have indicated that growth arrest-specific transcript 5 (GAS5) functions as a tumor suppressor and is aberrantly expressed in multiple cancers. GAS5 was found to be downregulated in gastric cancer (GC) tissues, and ectopic expression of GAS5 inhibited GC cell proliferation. AIMS: The present study aimed to explore the underlying mechanisms of GAS5 involved in GC cell proliferation. METHODS: GAS5 and miR-222 expressions in GC cell lines were estimated by quantitative real-time polymerase chain reaction. The effects of GAS5 and miR-222 on GC cell proliferation were assessed by MTT assay and 5-bromo-2-deoxyuridine (BrdU) incorporation assays. The interaction between GAS5 and miR-222 was confirmed by luciferase reporter assay and RNA immunoprecipitation assay. The protein levels of the phosphatase and tensin homolog (PTEN), phosphorylated protein kinase B (Akt) (p-Akt), Akt, phosphorylated mammalian target of rapamycin (mTOR) (p-mTOR), and mTOR were determined by western blot. RESULTS: GAS5 was downregulated and miR-222 was upregulated in GC cells. GAS5 directly targeted and suppressed miR-222 expression. GAS5 overexpression and miR-222 inhibition suppressed cell proliferation, increased PTEN protein level and decreased p-Akt and p-mTOR protein levels in GC cells while GAS5 knockdown and miR-222 overexpression exhibited the opposite effects. Moreover, mechanistic analyses revealed that GAS5 regulated GC cell proliferation through the PTEN/Akt/mTOR pathway by negatively regulating miR-222. CONCLUSIONS: GAS5/miR-222 axis regulated proliferation of GC cells through the PTEN/Akt/mTOR pathway, which facilitated the development of lncRNA-directed therapy against this deadly disease. FAU - Li, Yanhua AU - Li Y AD - Department of Oncology, Huaihe Hospital of Henan University, No. 8 Baobei Road, Kaifeng, 475000, Henan, People's Republic of China. FAU - Gu, Junjiao AU - Gu J AD - Department of Oncology, Huaihe Hospital of Henan University, No. 8 Baobei Road, Kaifeng, 475000, Henan, People's Republic of China. FAU - Lu, Hong AU - Lu H AD - Department of Oncology, Huaihe Hospital of Henan University, No. 8 Baobei Road, Kaifeng, 475000, Henan, People's Republic of China. honglu6512@163.com. LA - eng GR - 9412016Y1403/Science & Technology Department of Henan Province/International PT - Journal Article DEP - 20171102 PL - United States TA - Dig Dis Sci JT - Digestive diseases and sciences JID - 7902782 RN - 0 (GAS5 long non-coding RNA, human) RN - 0 (MIRN22 microRNA, human) RN - 0 (MicroRNAs) RN - 0 (RNA, Long Noncoding) RN - EC 2.7.1.1 (MTOR protein, human) RN - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt) RN - EC 2.7.11.1 (TOR Serine-Threonine Kinases) RN - EC 3.1.3.67 (PTEN Phosphohydrolase) RN - EC 3.1.3.67 (PTEN protein, human) SB - IM MH - Cell Line, Tumor MH - Gene Expression Regulation, Neoplastic MH - Humans MH - MicroRNAs/*metabolism MH - PTEN Phosphohydrolase/metabolism MH - Proto-Oncogene Proteins c-akt/metabolism MH - RNA, Long Noncoding/*metabolism MH - Stomach Neoplasms/*metabolism MH - TOR Serine-Threonine Kinases/metabolism OTO - NOTNLM OT - GAS5 OT - Gastric cancer OT - PTEN/Akt/mTOR pathway OT - Proliferation OT - miR-222 EDAT- 2017/11/04 06:00 MHDA- 2017/12/06 06:00 CRDT- 2017/11/04 06:00 PHST- 2017/07/27 00:00 [received] PHST- 2017/10/25 00:00 [accepted] PHST- 2017/11/04 06:00 [pubmed] PHST- 2017/12/06 06:00 [medline] PHST- 2017/11/04 06:00 [entrez] AID - 10.1007/s10620-017-4831-4 [pii] AID - 10.1007/s10620-017-4831-4 [doi] PST - ppublish SO - Dig Dis Sci. 2017 Dec;62(12):3426-3437. doi: 10.1007/s10620-017-4831-4. Epub 2017 Nov 2.